Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
about
Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis CComparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration.Interferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world settingCost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis.Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting.Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.Decreasing racial disparity with the combination of ledipasvir-sofosbuvir for the treatment of chronic hepatitis CTransformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents.Real world efficacy and safety of ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin IN genotype 1B patients with HCV liver cirrhosis.Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03).HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C.Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt.Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.Hepatitis C Virus Infection in the Older Patient.Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.Going Viral: Why Eliminating the Burden of Hepatitis C Requires Enhanced Cooperation Between Specialists and Primary Care Providers.Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients with Genotype 1 Hepatitis C Virus Infection and Cirrhosis.Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia.Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction.No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients.Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study.Race affects SVR12 in a large and ethnically diverse hepatitis C-infected patient population following treatment with direct-acting antivirals: Analysis of a single-center Department of Veterans Affairs cohort.Risk factors for familial clustering of hepatitis C virus infection in a Chinese Han population: a cross-sectional study.Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals
P2860
Q28552691-C0378325-477F-4396-B4AA-80F63BB58CFAQ31143582-893BB0CF-EEAD-4C6E-B9F4-D504B76E0569Q33646482-DFE90F54-BE9F-4075-83A1-68785F825D31Q33734454-9AEE2962-4547-48BE-9500-81D59A671F92Q33805907-F256D4E0-E8ED-4D17-A9DE-B13BF1E44B70Q33883646-C61353B9-EF5E-463B-8926-46EEE36E6997Q37714088-A83A1A0A-2913-4095-B52A-455AB864C1EFQ38405059-70DB1ADD-6E66-4BCE-BFB1-6777D5F3D967Q38620762-74D46124-2912-41BA-A029-46ED1D41A7D4Q38677852-3DC49873-971A-4C94-9F18-8DFEE12C17F6Q38692113-814B3FC7-987D-4FB9-943D-957CA311C06AQ38786225-3B35CAD6-BF5C-45B1-9E1C-8DE1A6250937Q38972499-41D2435F-754F-4768-8327-E5B164DB03D5Q39025575-725C2697-F4D3-4B6C-B5F4-05AC7036AA54Q39058953-7EA783B2-76B0-4713-96F7-0EEFABC34E56Q39134413-B7A9AFD6-9443-423A-B49D-B7885E63E23AQ39169232-2E3278D6-4219-455D-97D3-99288121BB0AQ39254698-00F5A683-1237-420C-AE59-1B43E4F86C59Q40050150-C694D4EA-774A-42B8-918D-E2756B544D58Q40091374-183CCF91-D4DF-4B9A-9AD7-B5445495C74DQ40129813-8604EAD3-0DC6-49B2-A98A-AF0E5B36292CQ40171277-33E78942-E6B9-45D1-B005-73A12FA101E6Q40285894-4B155880-D637-4567-AFEF-4128539C40C8Q40355278-4CF95335-70C0-4BE8-807B-06654A63A974Q41923679-38DA5030-395E-47AD-8029-0177A3C64F4DQ41930106-3CD73F86-0569-4FF1-832A-73D471E8F11DQ45325560-6D609320-BCD9-46EF-9C35-0873517039E0Q45326298-E76159A4-A47E-41C2-8B65-B988A77D2F24Q46257792-FC215296-169F-4C60-850A-F1CEBC8F35D6Q47202796-11B453A8-9D14-4954-A364-7404CCFB67A1Q47547115-A23DE05A-92D3-4E94-B95E-DF9E2C2EE22AQ47548361-675121AE-9117-4837-88AF-EFB6B4C64F7CQ47565629-2D55A4FC-5164-4732-B613-77F8B9F79543Q47605707-CB603F41-8F2B-42B2-847E-C16EE7B7383DQ51754955-9982F84F-7463-4E81-B646-B35F17DEC59BQ54256586-F98B04D0-0B97-424D-9320-1E39D3A8F5C6Q55050518-FA13A45C-CBDC-4735-B2AF-985942279600Q55259186-B6805A7D-6C3D-447C-BA4A-7D0713F51BFCQ55396689-97301754-98AD-445F-B61F-5C71F3ACF2AAQ57063280-28A97986-A113-4674-8091-3BA6AB15FAA5
P2860
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Effectiveness of Sofosbuvir, L ...... s National Health Care System.
@ast
Effectiveness of Sofosbuvir, L ...... s National Health Care System.
@en
type
label
Effectiveness of Sofosbuvir, L ...... s National Health Care System.
@ast
Effectiveness of Sofosbuvir, L ...... s National Health Care System.
@en
prefLabel
Effectiveness of Sofosbuvir, L ...... s National Health Care System.
@ast
Effectiveness of Sofosbuvir, L ...... s National Health Care System.
@en
P2093
P2860
P921
P1433
P1476
Effectiveness of Sofosbuvir, L ...... s National Health Care System.
@en
P2093
Elliott Lowy
George N Ioannou
Judith I Tsui
Kristin Berry
Lauren A Beste
Michael F Chang
Pamela K Green
P2860
P304
457-471.e5
P356
10.1053/J.GASTRO.2016.05.049
P407
P577
2016-06-04T00:00:00Z